SCHEMBL30706846

SCHEMBL30706846

C=C1CN2CCCC2(COc2ncc3cnccc3n2)C1

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 9/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29680448 0.86 KRAS (0.39) KRAS
SCHEMBL30391087 0.78 KRAS (0.47) KRAS
SCHEMBL30391045 0.78 KRAS (0.47) KRAS
SCHEMBL30391732 0.78 KRAS (0.47) KRAS
Hydrochloric Acid SCHEMBL30391165 0.77 KRAS (0.46) KRAS
SCHEMBL29634788 0.72 KRAS (0.45) KRAS
SCHEMBL31723994 0.70 KRAS (0.31) KRAS
SCHEMBL25419645 0.69 KRAS (0.40) KRAS
SCHEMBL30391500 0.69 KRAS (0.44) KRAS
SCHEMBL29418775 0.69 KRAS (0.40) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540255-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244615-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 — — WO disclosed
Send feedback